NHRI Vice President Sytwu Huey-kang. CNA file photo
Taipei, Jan. 15 (CNA) The Central Epidemic Command Center (CECC) is planning to launch a public-private partnership to develop and produce antibody treatments against COVID-19, according to the National Health Research Institutes (NHRI).
Speaking to the media on Friday, NHRI Vice President Sytwu Huey-kang (司徒惠康) said the treatments, which will be used to treat COVID-19 patients and also provide short-term immunity for healthy individuals, are seen as a vital stopgap treatment until vaccines become widely available.
Sytwu said the NHRI, Academia Sinica, National Taiwan University Hospital and Chang Gung Medical Foundation each began working to develop COVID-19 antibody treatments last year, but their efforts have been largely uncoordinated.
Medigen to begin phase 2 vaccine candidate trials
By Kao Shih-ching / Staff reporter
Medigen Vaccine Biologics Corp (高端疫苗) on Wednesday said it plans to begin phase 2 clinical trials next week for its COVID-19 vaccine candidate and expects to apply by the end of June for emergency use authorization for the drug.
The company has started recruiting participants after last week obtaining Food and Drug Administration (FDA) permission to launch the phase 2 trials.
The company plans to recruit 3,700 participants, the most ever in such trials in Taiwan, as it aims to effectively examine the efficacy of its vaccine over the next three months, it said.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the .
ZIOPHARM Oncology IncDecember 21, 2020 GMT
– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) –
– Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transfer –
BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that the Taiwan Food and Drug Administration has cleared an investigational new drug application (IND) from Eden BioCell, a joint venture between Ziopharm and cell therapy company TriArm Therapeutics, for its phase 1 clinical trial to evaluate patient-derived CD19-specific CAR-T, using Ziopharm’s Rapid Personalized Manufacturing (RPM) technology. Thi
228 Peace Memorial Park Full of Cultural Traces and Stories britainnews.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from britainnews.net Daily Mail and Mail on Sunday newspapers.